These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2568653)

  • 1. Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers.
    Grind M; Nilsson MI; Nilsson L; Oxenstierna G; Sedvall G; Wahlén A
    Psychopharmacology (Berl); 1989; 98(3):304-9. PubMed ID: 2568653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remoxipride: pharmacokinetics and effect on plasma prolactin.
    Movin-Osswald G; Hammarlund-Udenaes M
    Br J Clin Pharmacol; 1991 Sep; 32(3):355-60. PubMed ID: 1685665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remoxipride--a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers.
    Farde L; Grind M; Nilsson MI; Ogenstad S; Sedvall G
    Psychopharmacology (Berl); 1988; 95(2):157-61. PubMed ID: 2901121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of remoxipride.
    von Bahr C; Movin G; Yisak WA; Jostell KG; Widman M
    Acta Psychiatr Scand Suppl; 1990; 358():41-4. PubMed ID: 1978486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of urinary pH on the plasma and urinary kinetics of remoxipride in man.
    Widerlöv E; Termander B; Nilsson MI
    Eur J Clin Pharmacol; 1989; 37(4):359-63. PubMed ID: 2574673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and pharmacokinetics of remoxipride after intramuscular administration.
    Kahn JP; Yisak W; Albaret C; Nilsson L; Zaar-Hedin A; Laxenaire M
    Acta Psychiatr Scand Suppl; 1990; 358():51-3. PubMed ID: 1978489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers.
    von Bahr C; Wiesel FA; Movin G; Eneroth P; Jansson P; Nilsson L; Ogenstad S
    Psychopharmacology (Berl); 1991; 103(4):443-8. PubMed ID: 1676524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia.
    Widerlöv E; Andersson U; von Bahr C; Nilsson MI
    Psychopharmacology (Berl); 1991; 103(1):46-9. PubMed ID: 1672458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics.
    Soni SD; Tench D; Ashwood TJ; Movin G
    Acta Psychiatr Scand Suppl; 1990; 358():45-7. PubMed ID: 1978487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug interaction studies with remoxipride.
    Yisak W; von Bahr C; Farde L; Grind M; Mattila M; Ogenstad S
    Acta Psychiatr Scand Suppl; 1990; 358():58-62. PubMed ID: 1978492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentration of remoxipride in relation to antipsychotic effect and adverse symptoms. The Canadian Remoxipride Study Group.
    Jostell KG; Lapierre YD
    Acta Psychiatr Scand Suppl; 1990; 358():48-50. PubMed ID: 1978488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of remoxipride controlled release and immediate release capsules in schizophrenic patients.
    Widerlöv E; Franzén G; Jansson P; Movin G
    Int Clin Psychopharmacol; 1990 Apr; 5(2):125-34. PubMed ID: 1974271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state pharmacokinetics of controlled release and immediate release formulations of remoxipride in patients with chronic schizophrenia.
    Tench D; Soni SD; Ashwood T; Movin G
    Psychopharmacology (Berl); 1990; 101(1):132-6. PubMed ID: 1971445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
    Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
    J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of remoxipride in elderly psychotic patients.
    Movin G; Gustafson L; Franzén G; Widerlöv E; Soni SD; Tench D; Nilsson L; Yisak W
    Acta Psychiatr Scand Suppl; 1990; 358():176-80. PubMed ID: 1978480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride.
    Morrison D; Englund A; Lawrie V; Lewander T; Schlachet A; Westerbergh SE
    Acta Psychiatr Scand Suppl; 1990; 358():164-9. PubMed ID: 1978478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remoxipride in schizophrenia: effects on plasma prolactin.
    Chouinard G; Turnier L; Kallai-Sanfacon MA
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):599-603. PubMed ID: 2868493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients.
    King DJ; Devaney N; Cooper SJ; Blomqvist M; Mitchell MJ
    J Psychopharmacol; 1990 Jan; 4(2):83-9. PubMed ID: 22282932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High concentrations of remoxipride in lateral ventricles of rat after systemic administration.
    Ståhle L; Nilsson LB; Ogren SO
    Pharmacol Toxicol; 1992 Mar; 70(3):226-7. PubMed ID: 1349749
    [No Abstract]   [Full Text] [Related]  

  • 20. Single dose pharmacokinetics and tolerance of pancopride in healthy volunteers.
    Dewland P; Pérez Campos A; Martinez-Tobed A
    Arzneimittelforschung; 1995 Feb; 45(2):177-83. PubMed ID: 7710444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.